SHL Telemedicine (SHMLF) CEO reports multiple option awards

Rhea-AI Filing Summary

SHL Telemedicine Ltd CEO Arnon David has filed an initial ownership report showing existing equity awards, not new trades. The Form 3 lists several stock option grants over Ordinary Shares with exercise prices of CHF 2.75 and CHF 3.25, all expiring on September 5, 2030. These options are scheduled to become exercisable on different dates between September 5, 2025 and September 5, 2028, providing long-term, equity-based incentives tied to the company’s future share performance.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Arnon David

(Last) (First) (Middle)

KEHILAT LODGE 50

(Street)

TEL AVIV 6970672

(City) (State) (Zip)

ISRAEL

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
SHL TELEMEDICINE LTD [ SHLT ]

3a. Foreign Trading Symbol
[SHLTN]

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option	09/05/2025	09/05/2030	Ordinary Shares	50,000	$3.25(1)	D
Option	09/05/2025	09/05/2030	Ordinary Shares	50,000	$2.75(1)	D
Option	09/05/2026	09/05/2030	Ordinary Shares	50,000	$3.25(1)	D
Option	09/05/2026	09/05/2030	Ordinary Shares	50,000	$2.75(1)	D
Option	09/05/2027	09/05/2030	Ordinary Shares	50,000	$3.25(1)	D
Option	09/05/2027	09/05/2030	Ordinary Shares	50,000	$2.75(1)	D
Option	09/05/2028	09/05/2030	Ordinary Shares	50,000	$3.25(1)	D
Option	09/05/2028	09/05/2030	Ordinary Shares	50,000	$2.75(1)	D

Explanation of Responses:

1. The exercise price is in CHF.

Remarks:

This Form 3 is filed pursuant to the Holding Foreign Insiders Accountable Act (HFIAA), which extends Section 16(a) reporting obligations to directors and officers of Foreign Private Issuers effective March 18, 2026.

	/s/ David Arnon	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the SHL Telemedicine (SHMLF) Form 3 filing show?

The Form 3 shows CEO Arnon David’s existing holdings of stock options in SHL Telemedicine. It lists multiple option awards over Ordinary Shares, with specified exercise prices, vesting dates, and a common expiration date in 2030, but no new share purchases or sales.

Did SHL Telemedicine CEO Arnon David buy or sell shares in this Form 3?

No, this Form 3 does not report any share purchases or sales by CEO Arnon David. It only provides an initial statement of his existing stock option awards, which are derivative securities tied to SHL Telemedicine’s Ordinary Shares.

What option exercise prices are disclosed for SHL Telemedicine CEO in the Form 3?

The Form 3 discloses option exercise prices of CHF 2.75 and CHF 3.25 for CEO Arnon David. A footnote clarifies that these exercise prices are denominated in Swiss francs, reflecting the currency applicable to the option terms.

When do the SHL Telemedicine CEO’s options expire according to the Form 3?

All of the reported stock options held by SHL Telemedicine CEO Arnon David expire on September 5, 2030. The filing also shows different exercise (vesting) dates between 2025 and 2028 before this final expiration date.

What underlying security is linked to the SHL Telemedicine CEO’s options?

The options reported in the Form 3 are all linked to SHL Telemedicine’s Ordinary Shares as the underlying security. Each option award references a specific number of underlying Ordinary Shares that could be acquired upon exercise.

Is the SHL Telemedicine Form 3 filing a major market-moving event?

The Form 3 is primarily administrative, establishing CEO Arnon David’s initial option holdings. It does not disclose new trades or large ownership changes, so it is generally viewed as routine rather than a major market-moving development.